Welcome to our dedicated page for Biomea Fusion news (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion stock.
Biomea Fusion, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for diabetes, obesity and related metabolic diseases. Its updates center on icovamenib, an investigational oral covalent menin inhibitor being evaluated in type 1 and type 2 diabetes, and BMF-650, an investigational oral GLP-1 receptor agonist candidate for obesity.
Recurring announcements include COVALENT trial results and study initiations, measures of beta-cell function, C-peptide, glycemic control and safety, scientific presentations at diabetes and metabolic-disease meetings, investor-conference activity, and periodic financial results with pipeline updates.
Biomea Fusion reported promising preclinical findings for BMF-500, its investigational covalent FLT3 inhibitor, highlighting its potential as the most potent and selective FLT3 inhibitor to date. Key results indicate that BMF-500 achieves greater cytotoxicity in acute myeloid leukemia (AML) cell lines compared to gilteritinib, and demonstrates sustained FLT3 inhibition, leading to complete tumor regression in mouse models. With around one-third of AML patients affected by FLT3 mutations, the company aims to file an IND for BMF-500 in early 2023, potentially enhancing treatment options in this critical area.
Biomea Fusion (Nasdaq: BMEA) announced a significant milestone with the dosing of the first patient in the Phase II trial of BMF-219 for type 2 diabetes. This therapy targets menin, a protein inhibiting beta cell regeneration, a critical aspect of diabetes pathology. Following a successful Phase I trial, the company plans to file an IND with the FDA to expand the trial to U.S. sites by Q4 2022. Initial Phase II data is expected in the first half of 2023, addressing a global need for innovative diabetes treatments.
Biomea Fusion (Nasdaq: BMEA) recently announced the dosing of its first patient with chronic lymphocytic leukemia (CLL) in the COVALENT-101 trial, evaluating the investigational covalent menin inhibitor BMF-219. This expanded trial aims to address the high unmet need in relapsed/refractory CLL patients. Preclinical data showed BMF-219's potent cell lethality across various CLL models, demonstrating nearly 100% efficacy even against samples resistant to standard treatments. CEO Thomas Butler emphasized the potential of BMF-219 as a transformative therapy for CLL.
Biomea Fusion has received FDA clearance for its Investigational New Drug (IND) application for BMF-219, a covalent menin inhibitor targeting KRAS solid tumors. The company will initiate a Phase I/Ib clinical trial (COVALENT-102) for patients with unresectable NSCLC, CRC, and PDAC bearing KRAS mutations. This trial expands BMF-219's scope, which also includes a Phase I trial in blood cancers. BMF-219 is notable as the first menin inhibitor entering solid tumor trials, with preclinical studies demonstrating strong anti-cancer activity against various KRAS mutations.
Biomea Fusion (Nasdaq: BMEA) reported promising findings for its diabetes treatment BMF-219 at the EASD Annual Meeting, showcasing its capability to enhance pancreatic beta cell mass and function in preclinical models. In rat studies, BMF-219 exhibited significant improvements in insulin sensitivity, glycemic control, and sustained beta cell function, outperforming existing treatments like pioglitazone. The company plans to file an IND for BMF-219 in type 2 diabetes by late 2022, highlighting its potential as a long-acting, disease-modifying therapy for diabetes.
Biomea Fusion (Nasdaq: BMEA) presented new preclinical data on BMF-219, a covalent menin inhibitor, at the EASD Annual Meeting in Stockholm, demonstrating its ability to improve pancreatic beta cell function and glycemic control in a diabetic rat model. Over 4 weeks, BMF-219 significantly reduced HbA1c by 3.5% compared to liraglutide's 1.7%, along with improvements in fasting glucose and weight loss. The company aims to file an IND for BMF-219 in Type 2 Diabetes by late 2022, showcasing its potential as a disease-modifying oral treatment.
Biomea Fusion presented significant findings at the 19th International Myeloma Society Annual Meeting (August 25-27, 2022). BMF-219 demonstrated robust anti-tumor activity, achieving over 90% inhibition in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple myeloma (MM). The ongoing Phase I clinical trial, COVALENT-101, aims to explore BMF-219’s effects on patients with relapsed/refractory cancers. The preclinical results underscore BMF-219’s potential as a first-in-class menin inhibitor, indicating a promising future for its clinical applications.
Biomea Fusion (Nasdaq: BMEA) reported significant advancements in its clinical pipeline, focusing on BMF-219, a covalent menin inhibitor. The COVALENT-101 Phase I study is enrolling patients for various malignancies, with IND submissions for solid tumors and type 2 diabetes expected soon. Financial results show a net loss of $33.6 million for H1 2022, up from $14.3 million in H1 2021, primarily due to increased R&D expenses. Cash reserves stand at $150.2 million, down from $175.7 million at year-end 2021, indicating ongoing investment in product development and operational expansion.
Biomea Fusion (BMEA) announced significant findings from two oral presentations at the EASD Annual Meeting, showcasing its drug BMF-219. The preclinical studies reveal that BMF-219, a covalent menin inhibitor, achieves a 50% reduction in blood glucose levels and a notable 3.5% reduction in HbA1C, surpassing existing treatments like liraglutide. This novel treatment maintains glycemic control even after treatment cessation. The company plans to initiate a Phase I/II clinical trial in the second half of 2022, pending IND submission and clearance.
Biomea Fusion announced the first patient dosing in its Phase I clinical trial, COVALENT-101, evaluating BMF-219, a covalent menin inhibitor, for relapsed/refractory multiple myeloma (MM). This marks BMF-219 as the first menin inhibitor targeting MM. The trial has expanded to include cohorts for both MM and diffuse large B-cell lymphoma (DLBCL), while patient enrollment continues for acute leukemia cohorts. Approximately 35,000 new MM cases are diagnosed annually in the U.S., with a notably low 5-year survival rate of ~56% for affected patients.